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Abstract
Background: Plasmodium falciparum resistance to drugs remains a major public health issue in
Niger. The therapeutic failure index for chloroquine and sulphadoxine-pyrimethamine are,
respectively 20% and 21.9%. In December 2005, the National Malaria Control Programme
promoted the use of artemisinin combination therapy (ACT) as first-line treatment of the
uncomplicated malaria cases. Recently, studies have shown a relationship between the SERCA
PfATPase6 gene and artemisinin efficacy, and pointed it out as a potential molecular marker for
resistance. The goal of this work was to describe the baseline polymorphism of PfATPase6 gene in
Niger, at a time when the national implementation of the ACT policy had just begun.
Materials and methods: The DNA polymorphism of the PfATPase6 gene of 87 P. falciparum
samples from Niger was analysed by sequencing. The links between the mutation occurrence and
environment and human host factors were tested by bivariate analysis.
Results: The P. falciparum PfATPase6 gene presented polymorphisms at codons 537, 561, 569, 630,
639, 716 levels. All the mutations found were rare, except the PfATPaseN569K found in 17.2% of
samples. No associated factor has been observed.
Conclusion: The P. falciparum PfATPase gene is polymorphic at the 569 codon. As ACT is getting
more and more used, the PfATPase6 gene polymorphism needs to be monitored in association with
phenotypic – in vivo and/or in vitro – drug efficacy tests.
Background
For many diseases, the history of anti-infectious drugs
shows us that the resistance to treatment does appear after
a more or less long time. This is the case for HIV, tubercu-
losis and, in this case, malaria [1]. The World Health
Organization (WHO) recommends the use of therapeutic
combination with artemisinin derivatives for a better effi-
cacy and to delay the occurrence of resistance by exploit-
ing the synergic and/or additive properties of the
constituent drugs [2]. The pfATPase is an ATPase-depend-
ent ionic pump from the Plasmodium endoplasmic reticu-
lum membrane related to cations transport. The
artemisinin and derivatives should negatively regulate this
cationic pump [3]. Until recently, only six SNPs of PfAT-
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Pase were known [4,5]. The pfATPase6S769N mutation
has been found strongly associated with artemether high
IC50s in French Guyana [4] and has been proposed as a
molecular marker of resistance against artemisinin. The
Xenopus model [6] and docking simulation [7] suspected
the 263 codon to be involved in the binding of artemisins
to PfATPase6. Noting that this mutation site was never
found involved in field studies, Data regarding sequences
of African samples reported several mutation points: Jam-
bou and et al [4] and Ferreira et al [5], respectively,
sequenced 16 Senegalese samples and eight samples from
Sao Tomé. Cojean et al [8] reported sequencing partial
results of 154 samples, mainly from West Africa. From
these three studies, only six mutation points were found.
Recently, Dhalstrom et al [9] added the results of
sequences of 345 East African and 10 West African sam-
ples, increasing the number of known SNPs to 33. Among
these, three SNPs were found with a higher than 5% per-
centage of mutations: the codons H431K, N569K and
A630S.
In Niger, the resistance of Plasmodium falciparum to treat-
ment is a major public health issue. At the beginning of
this century, a 20% therapeutic failure index for chloro-
quine has been found among children under five years of
age [10,11]. Molecular monitoring of treatment efficacy
showed 45.7% of pfcrtK76T  and 60.2% of pdhfrS108N
[12] at the Niamey National Hospital. In the Niger Valley,
these molecular markers turned out having respective
prevalences of 50.8% and 57.7% [13]. Furthermore, a
DNA-microarray study, targeting 34 P. falciparum resist-
ance-associated SNPs and including PfATPase  codons,
showed a clear increase of resistance to chloroquine and
to sulphadoxine/pyrimethamine over a four-years period
[14]. In December 2005, Niger has switched as its first-
line treatment policy for uncomplicated cases of malaria
to the use of artemisinin-based combination therapy
(ACT). Having started in 2006, the implementation has
now reached the whole country. The main goal of the
study, performed at a time when the national implemen-
tation of the ACT policy had just begun, was to describe
the genetic polymorphism of the pfATPase6 gene. This
should provide useful baseline data for the malaria resist-
ance monitoring network (RSRA), [13] set-up in Niger in
2002 and included in the framework of the West African
malaria resistance survey network, RAOTAP II.
Methods
Samples
Ninety two P. falciparum microscopy-positive samples
from asymptomatic carriers have been tested. They were
all coming from two villages of Sahel in south-west Niger.
The two villages differed by the duration of the malaria
transmission: short (two to three months) in Banizoum-
bou and longer (six months) in Zindarou. The samples
were stratified by age (younger than 10 years old and
equal and older than 10 years old), by village (Banizoum-
bou/Zindarou), by year (2003/2006) and by parasitaemia
classes (below 1,000 parasites/μl and above 1,000 para-
sites/μl). Ethical clearance was obtained from the
National Ethics Committee of Niger.
DNA extraction
The DNA from the finger prick blood dried on filter cards
was extracted in 96 well-plates by resin (Instagen). Briefly,
dried red blood cells were first treated by lysis buffer
HBS1%/saponine 10% (HEPES 100mM, NaCl 1.4M, KCl
100mM) and washed three times. The parasites pellets
have been heated (56°C then 90°C) with 200 μl of Insta-
gen resin. Finally the DNA was purified by centrifugation
during 20 minutes.
PCR amplification and sequencing
A nested PCR allowed the amplification of a portion of
the PfATPase gene. The primary PCR allows the produc-
tion of 896 pb amplicon with primers P17.1 for 5'-
TGGATCAATAATACCTAATCCACCTA-3' and P17.1rev:
5'-AATATTGTTATTCAGA ATATGATTAT AA-3'. The nested
PCR with internal primers P17 for 5'-AGCAAATATT TTCT-
GTAACGATAATA-3' and P17 rev 5'-TGTTCTAATT-
TATAATAATCATCTGT-3' amplified a 798 pb amplicon
which was sequenced in the South Korea Biotechnology
Institute. Most of the mutations found in field samples
were described in that zone, including codons for the
cytoplasmic domain of the PfATPase6 [15].
Analysis
Data were included in a data file with EPI-INFO v. 6.0 and
bivariate relations were analysed by the Chi-square or
Fisher exact tests.
Results
Samples characteristics
Fifty percent of the 92 samples came from Zindarou and
the other half from Banizoumbou. The mean age was 13
years old and the F/M sex ratio was 1.35. The mean para-
sitaemia was 2,681 parasites/μl.
Genetic polymorphism and global prevalence of mutations
Sequencing was successful in 87 samples. Genetic poly-
morphism was found at six codons of the PfATPase gene:
537, 561, 569, 630, 639 and 716. The mutation at 537
codon did not lead to any potential protein change. The
five others led to protein change. Among these, two are
newly described: K561N and K716R. The prevalence of
the different mutations at the 537, 561, 630, 639, and 716
codons was only 1.1% (1/87). The mutation PfATPase
N569K prevalence was 17.2% (Table 1). Only one sample
was carrying two mutations: N569K and G639D.Malaria Journal 2009, 8:28 http://www.malariajournal.com/content/8/1/28
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Bivariate relation of PfATPase N569K according to 
parasitaemia, age, village and year
Neither the parasitaemia, nor the sex, nor the age, nor the
villages, nor the collection years were related to the PfAT-
Pase N569K mutation.
Discussion
This study describes for the first time a PfATPase6 gene
sequence polymorphism in Niger. It increases the number
of West African samples sequences and mutations points,
adding three new mutations points: 537, 561 and 716.
Among the six different observed mutations, only one, the
N569K mutation, was relatively frequent – 17.2% of iso-
lates. Dahlstrom et al [9] had also found a high prevalence
of this mutation in Zanzibar (36%) and Tanzania (29%).
This codon was out of the Menegon et al [16] studied gene
zone, as were the two new found 357 and 561 mutations.
The pfATPaseS769N mutation was absent in these Niger
samples, as it had been shown in China [17] and in Tan-
zania tested either by DNA-microarrays [18] or by
sequencing [9]. The pfATPaseS769N mutation has been
recently described as a potential molecular marker for P.
falciparum resistance to artemisinin [4]. The quasi-absence
of this mutation in African samples [19] – since its first
report, it had only been found once by Cojean et al [8] –
did not disprove this hypothesis. Recently, a study from
Menegon et al [16], carried out a polymorphism study of
PfATPase in African isolates at codons 402 and 431, which
the present work did not target. In the Niger study, there
was no correlation between this mutation and other fac-
tors, such as village, age or time of collection. These fac-
tors have been correlated with chloroquine and
pyrimethamine resistance in previous work [14]. The
same previous study checked for five PfATPase6 gene SNPs
(538, 574, 623, 683 and 769) by DNA-microarrays [20].
By DNA-microarrays, the pfATPaseA623E  mutation was
found in 4.7% of the Niger samples [14], but sequencing
did not confirm this.
The present work showed six different mutations for 87
samples of Niger, while Dahlstrom et al found 31 among
302 samples in Zanzibar and three among 39 Tanzanian
samples [9]. Menegon et al found seven mutations sites
for 71 specimens from west, central and south-east Africa
[16], including Madagascar. All these figures are compara-
ble and, in a given geographical zone, such molecular var-
iation has to be linked with the sampling effort, the
number of samples, but also of sequenced base pairs in a
given genomic area.
Conclusion
The present work did not show the S769N mutation, pres-
ently candidate as a molecular marker for artemether
resistance. However, the molecular diversity of PfATP6
seems more pronounced than previously demonstrated.
The variable genetic background needed for the artemisi-
nin-driven selection of resistant variants could be present
in Africa. At a time when almost all African countries have
adopted artemisinin derivatives as first-line treatment, the
molecular monitoring of the PfATP6  gene is of prior
importance. The baseline data established before the ACT
implementation will support ulterior comparison.
Among the highlighted mutations, the N569K mutation
presents notable occurrences both in West and East Africa.
Future functional studies, such as docking simulation and
binding affinity, may be useful for prediction of the
impact of the diverse mutations and the design of future
molecular monitoring tools supporting the national con-
trol programmes.
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